Anbio Biotechnology (NNNN) vs JIN MEDICAL INTERNATIONAL LTD. (ZJYL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) has outperformed Anbio Biotechnology (NNNN) over the past year, losing 76.3% versus a loss of 84.3%. Anbio Biotechnology is the larger company by market cap ($204.5 million vs $153.8 million), about 1.3 times the size. On valuation, JIN MEDICAL INTERNATIONAL LTD. trades at a lower trailing P/E (10.8x vs 31.1x for Anbio Biotechnology).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | ZJYL |
|---|---|---|
| Share price | $4.66 | $2.06 |
| Market cap | $204.53M | $153.81M |
| 1-day change | +0.87% | -2.83% |
| YTD return | -84.50% | -53.18% |
| 1-year return | -84.25% | -76.32% |
| P/E ratio (TTM) | 31.07 | 10.84 |
| EPS (TTM) | $0.15 | $0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $8.96 |
| 52-week low | $4.20 | $1.53 |
| Distance from 52-week high | -89.58% | -77.01% |
| Average volume | 148.28K | 734.62K |
| Shares outstanding | 43.89M | 73.66M |
| Employees | 27 | 273 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Anbio Biotechnology trades at a higher earnings multiple (31.1x vs 10.8x trailing P/E).
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About JIN MEDICAL INTERNATIONAL LTD.
ZJYL stock →Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids for people with disabilities, the elderly, and people recovering from injury.
Health Care · Industrial Specialties · 273 employees
NNNN vs ZJYL FAQ
Which is bigger, Anbio Biotechnology or JIN MEDICAL INTERNATIONAL LTD.?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $204.53M compared with $153.81M for JIN MEDICAL INTERNATIONAL LTD. (ZJYL).
Which stock has performed better over the past year, NNNN or ZJYL?
ZJYL returned -76.32% over the past 12 months, compared with -84.25% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NNNN or ZJYL?
ZJYL has the lower trailing P/E at 10.8, versus 31.1 for NNNN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Anbio Biotechnology and JIN MEDICAL INTERNATIONAL LTD. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology and Industrial Specialties for JIN MEDICAL INTERNATIONAL LTD..